scispace - formally typeset
N

Nawaid Usmani

Researcher at Cross Cancer Institute

Publications -  150
Citations -  2902

Nawaid Usmani is an academic researcher from Cross Cancer Institute. The author has contributed to research in topics: Prostate cancer & Prostate brachytherapy. The author has an hindex of 23, co-authored 130 publications receiving 1973 citations. Previous affiliations of Nawaid Usmani include University of Alberta & Queen's University.

Papers
More filters
Journal ArticleDOI

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Fredrick R. Schumacher, +207 more
- 11 Jun 2018 - 
TL;DR: A large meta-analysis combining genome-wide and custom high-density genotyping array data identifies 63 new susceptibility loci for prostate cancer, enhancing fine-mapping efforts and providing insights into the underlying biology of PrCa1.
Journal ArticleDOI

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

David V. Conti, +254 more
- 04 Jan 2021 - 
TL;DR: This paper conducted a meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants.
Journal ArticleDOI

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Tokhir Dadaev, +339 more
TL;DR: The authors perform multivariate fine-mapping of known PrCa GWAS loci, identifying variants enriched for biological function, explaining more familial relative risk, and with potential application in clinical risk profiling.
Journal ArticleDOI

Determinants of the nuclear localization of the heterodimeric DNA fragmentation factor (ICAD/CAD).

TL;DR: A complex mechanism, involving the recognition of the NLSs of both ICAD and CAD, accounts for the constitutive accumulation of CAD/ICAD in the nucleus, where caspase-3–dependent regulation of CAD activity takes place.